Corbus Pharmaceuticals Shares - analyst consensus snapshot
18.06.2026 - 22:20:00 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/18/2026, 20:19 UTC. Details in the imprint.
Corbus Pharmaceuticals (US21833E1038) has a fresh analyst consensus snapshot in the market data used for this article. TradingKey lists the stock at $8.20 and says analysts rate it Strong Buy, with a $38.44 target.
Background and price data on Corbus Pharmaceuticals
Track the latest company coverage, market data, and investor resources in one place.
Analyst view
TradingKey’s market page shows Corbus Pharmaceuticals with a Strong Buy consensus and a $38.44 average target. The same page lists the stock at $8.20, based on delayed quotes.
Thursday chart focus
The Thursday module centers on chart context. No live technical level was independently verified in the supplied results, so the article stays with the consensus readout and the quoted price.
What the company develops
Corbus Pharmaceuticals is a clinical-stage biotech focused on drug development. Its portfolio includes CRB-701, a next-generation antibody-drug conjugate, and CRB-401 in its pipeline messaging.
Where the stock trades today
The shares of Corbus Pharmaceuticals (US21833E1038) trade on Nasdaq at $8.20 as of 06/18/2026, 20:19 UTC.
Key facts on Corbus Pharmaceuticals stock
- Company: Corbus Pharmaceuticals Holdings, Inc.
- ISIN: US21833E1038
- Ticker: CRBP
- Venue: Nasdaq
- Price (as of 06/18/2026, 20:19 UTC): $8.20
- Market cap: $145.46M
- Index membership: not verified
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
